Advance in the Treatment of Pediatric Leukemia
The book gives an overview on the progress that has been made in the treatment of acute lymphoblastic leukemia (ALL), of acute and chronic myeloid leukemia (AML, CML) and of juvenile myelomonocytic leukemia (JMML). Leukemia is the most common malignant disease in children, and 80% of patients are di...
Saved in:
Sonstige: | |
---|---|
Year of Publication: | 2022 |
Language: | English |
Physical Description: | 1 electronic resource (300 p.) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993544747604498 |
---|---|
ctrlnum |
(CKB)5720000000008386 (oapen)https://directory.doabooks.org/handle/20.500.12854/84555 (EXLCZ)995720000000008386 |
collection |
bib_alma |
record_format |
marc |
spelling |
Handgretinger, Rupert edt Advance in the Treatment of Pediatric Leukemia Basel MDPI - Multidisciplinary Digital Publishing Institute 2022 1 electronic resource (300 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier Open access Unrestricted online access star The book gives an overview on the progress that has been made in the treatment of acute lymphoblastic leukemia (ALL), of acute and chronic myeloid leukemia (AML, CML) and of juvenile myelomonocytic leukemia (JMML). Leukemia is the most common malignant disease in children, and 80% of patients are diagnosed with ALL and 15–20% with AML, whereas CML and JMML are rather rare. Although ALL was considered an incurable disease until the early 1960s, with the availability of cytotoxic drugs and the start of clinical multicenter studies, ALL has become an almost curable disease with a survival rate exceeding 90 % in high-income countries. These impressive results have mainly been achieved by a deeper understanding of the genomic landscape of the disease and the introduction of risk stratifications based on genetic features and response to chemotherapy as determined by the presence or absence of minimal residual disease (MRD). Immunotherapies including bispecific T-cell Engagers (BiTEs), Chimeric Antigen Receptor (CAR) T cells, monoclonal antibodies and improvements in the outcome of allogeneic stem cell transplantation (HSCT) have shown impressive results in chemorefractory or relapsed patients, and it is anticipated that the cure rate can be further increased. For countries with less resources, therapies have to be adapted to increase survival as well. This book also updates on the progress made in the treatment of AML. As in ALL, risk classification based on genetic factors and response to chemotherapy is most important for therapy guidance. The book also provides updates and guidance for the treatment of CML and JMML. English Research & information: general bicssc Chemistry bicssc acute lymphoblastic leukemia pediatric advances diagnosis treatment immunotherapy bispecific T-cell engager (BiTE) BCP-ALL leukemia TRAIL antibody Fc-engineering xenograft CD19 juvenile myelomonocytic leukemia RAS signaling hematopoietic stem cell transplantation 5-azacitidine myelodysplastic/myeloproliferative disorders targeted therapy ADC antibody-drug conjugate pediatric leukemia ALL AML allogeneic stem cell transplantation acute myeloid leukemia minimal residual disease conditioning regimen alternative donors B-ALL DUX4 IKZF1 PAX5 Ph-like ZNF384 NUTM1 T-ALL NOTCH1 BCL11B transcriptome genome chronic myeloid leukemia CML tyrosine kinase inhibitor immunizations COVID-19 childhood acute lymphoblastic leukemia low-risk ALL risk-stratified treatment treatment related toxicity L-asparaginase acute pancreatitis polymorphism SNV ABCC4 CFTR other extramedullary relapse lymphoblastic leukemia children prognosis evolution of CAR T cells FDA-approved CAR products TcR versus CAR limitations and complications of CAR T cell therapy future directions of CAR T cell therapy 3-0365-4167-5 3-0365-4168-3 Handgretinger, Rupert oth |
language |
English |
format |
eBook |
author2 |
Handgretinger, Rupert |
author_facet |
Handgretinger, Rupert |
author2_variant |
r h rh |
author2_role |
Sonstige |
title |
Advance in the Treatment of Pediatric Leukemia |
spellingShingle |
Advance in the Treatment of Pediatric Leukemia |
title_full |
Advance in the Treatment of Pediatric Leukemia |
title_fullStr |
Advance in the Treatment of Pediatric Leukemia |
title_full_unstemmed |
Advance in the Treatment of Pediatric Leukemia |
title_auth |
Advance in the Treatment of Pediatric Leukemia |
title_new |
Advance in the Treatment of Pediatric Leukemia |
title_sort |
advance in the treatment of pediatric leukemia |
publisher |
MDPI - Multidisciplinary Digital Publishing Institute |
publishDate |
2022 |
physical |
1 electronic resource (300 p.) |
isbn |
3-0365-4167-5 3-0365-4168-3 |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT handgretingerrupert advanceinthetreatmentofpediatricleukemia |
status_str |
n |
ids_txt_mv |
(CKB)5720000000008386 (oapen)https://directory.doabooks.org/handle/20.500.12854/84555 (EXLCZ)995720000000008386 |
carrierType_str_mv |
cr |
is_hierarchy_title |
Advance in the Treatment of Pediatric Leukemia |
author2_original_writing_str_mv |
noLinkedField |
_version_ |
1787548495997042688 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04794nam-a2201105z--4500</leader><controlfield tag="001">993544747604498</controlfield><controlfield tag="005">20231214133236.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202206s2022 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5720000000008386</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/84555</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995720000000008386</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Handgretinger, Rupert</subfield><subfield code="4">edt</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Advance in the Treatment of Pediatric Leukemia</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Basel</subfield><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute</subfield><subfield code="c">2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (300 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="506" ind1=" " ind2=" "><subfield code="a">Open access</subfield><subfield code="f">Unrestricted online access</subfield><subfield code="2">star</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The book gives an overview on the progress that has been made in the treatment of acute lymphoblastic leukemia (ALL), of acute and chronic myeloid leukemia (AML, CML) and of juvenile myelomonocytic leukemia (JMML). Leukemia is the most common malignant disease in children, and 80% of patients are diagnosed with ALL and 15–20% with AML, whereas CML and JMML are rather rare. Although ALL was considered an incurable disease until the early 1960s, with the availability of cytotoxic drugs and the start of clinical multicenter studies, ALL has become an almost curable disease with a survival rate exceeding 90 % in high-income countries. These impressive results have mainly been achieved by a deeper understanding of the genomic landscape of the disease and the introduction of risk stratifications based on genetic features and response to chemotherapy as determined by the presence or absence of minimal residual disease (MRD). Immunotherapies including bispecific T-cell Engagers (BiTEs), Chimeric Antigen Receptor (CAR) T cells, monoclonal antibodies and improvements in the outcome of allogeneic stem cell transplantation (HSCT) have shown impressive results in chemorefractory or relapsed patients, and it is anticipated that the cure rate can be further increased. For countries with less resources, therapies have to be adapted to increase survival as well. This book also updates on the progress made in the treatment of AML. As in ALL, risk classification based on genetic factors and response to chemotherapy is most important for therapy guidance. The book also provides updates and guidance for the treatment of CML and JMML.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Research & information: general</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Chemistry</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">acute lymphoblastic leukemia</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pediatric</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">advances</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">diagnosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">treatment</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">bispecific T-cell engager (BiTE)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">BCP-ALL</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">leukemia</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">TRAIL</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antibody</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Fc-engineering</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">xenograft</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CD19</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">juvenile myelomonocytic leukemia</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">RAS signaling</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">hematopoietic stem cell transplantation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">5-azacitidine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">myelodysplastic/myeloproliferative disorders</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">targeted therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ADC</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antibody-drug conjugate</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pediatric leukemia</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ALL</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">AML</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">allogeneic stem cell transplantation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">acute myeloid leukemia</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">minimal residual disease</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">conditioning regimen</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">alternative donors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">B-ALL</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">DUX4</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">IKZF1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PAX5</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Ph-like</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ZNF384</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">NUTM1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">T-ALL</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">NOTCH1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">BCL11B</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">transcriptome</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">genome</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">chronic myeloid leukemia</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CML</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tyrosine kinase inhibitor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunizations</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">COVID-19</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">childhood acute lymphoblastic leukemia</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">low-risk ALL</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">risk-stratified treatment</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">treatment related toxicity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">L-asparaginase</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">acute pancreatitis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">polymorphism</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">SNV</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ABCC4</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CFTR</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">other extramedullary relapse</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">lymphoblastic leukemia</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">children</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prognosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">evolution of CAR T cells</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">FDA-approved CAR products</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">TcR versus CAR</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">limitations and complications of CAR T cell therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">future directions of CAR T cell therapy</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-4167-5</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-4168-3</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Handgretinger, Rupert</subfield><subfield code="4">oth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:47:28 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-07-02 22:45:44 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5337746870004498&Force_direct=true</subfield><subfield code="Z">5337746870004498</subfield><subfield code="b">Available</subfield><subfield code="8">5337746870004498</subfield></datafield></record></collection> |